metsera novo nordisk - Search News

Pfizer considers suing Metsera, Novo over topping bid

Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement

The lawsuit also alleges that the proposed special dividend contemplated by Novo Nordisk’s proposal is a violation of Delaware law and that the Metsera Directors have breached their fiduciary duties ...

· 1d · on MSN

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera

· 1d · on MSN

Metsera says Novo Nordisk’s $9B buyout offer “superior”; Pfizer calls bid “illusory”

· 1d

Novo Nordisk says offer for Metsera adheres to restrictions under Pfizer deal

Reporting by Jacob Gronholt-Pedersen and Stine Jacobsen, writing by Louise Breusch Rasmussen, editing by Essi Lehto

· 1d

Novo Nordisk enters bidding war with Pfizer over US biotech Metsera

STAT · 1d

Novo Nordisk makes offer for obesity-focused Metsera, aiming to outbid Pfizer

· 1d

Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera

Following the announcement, Metsera said the offer from Novo Nordisk was "superior", as defined in its merger agreement with Pfizer, and gave Pfizer four business days to submit a new, higher offer.

· 1d

Novo Nordisk launches bidding war with Pfizer for US obesity biotech Metsera

· 1d

Pfizer considers suing Metsera, Novo over topping bid - report

PharmExec

Pharmaceutical Executive Daily: Novo Nordisk's Unsolicited Acquisition Proposal

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’s manufacturer following statements from Robert F. Kennedy Jr., and AbbVie’s stronger 2025 profit outlook driven by immunology demand.

23h

Novo: Risks Revisited And Potential Metsera Deal

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward trends. Click for my NVO stock update.